eprintid: 10157002 rev_number: 10 eprint_status: archive userid: 699 dir: disk0/10/15/70/02 datestamp: 2022-10-10 07:33:34 lastmod: 2023-08-16 14:56:37 status_changed: 2022-10-10 07:33:34 type: article metadata_visibility: show sword_depositor: 699 creators_name: Gardner, Annelys Roque creators_name: Ma, Yifei creators_name: Bacchetti, Peter creators_name: Price, Jennifer C creators_name: Kuniholm, Mark H creators_name: French, Audrey L creators_name: Gange, Stephen creators_name: Adimora, Adaora A creators_name: Minkoff, Howard creators_name: Kassaye, Seble creators_name: Ofotokun, Igho creators_name: Rosenberg, William creators_name: Kovacs, Andrea AZ creators_name: Tien, Phyllis C title: Longitudinal Assessment of the Enhanced Liver Fibrosis Score in the Era of Contemporary HIV and Hepatitis C Virus Treatment ispublished: pub divisions: C10 divisions: G91 divisions: B02 divisions: UCL divisions: D17 keywords: APRI, ELF, FIB-4, HIV, direct-acting antiviral therapy, enhanced liver fibrosis score, hepatitis C note: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. abstract: BACKGROUND: The trajectory of liver fibrosis is not well understood in the contemporary era of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) therapy. METHODS: We assessed the Enhanced Liver Fibrosis (ELF) score, aspartate transaminase-to-platelet ratio index (APRI) and Fibrosis-4 (FIB-4) in 116 women with HIV/HCV coinfection over a 4-year period. Random-effects linear regression models examined the rate of fibrosis change 1-2 years before starting HCV treatment, within 1 year before starting (peri-HCV treatment), within 1 year after and 1-2 years post-HCV treatment in unadjusted and adjusted models including age, race, and changes from pretreatment of factors that might affect fibrosis (eg, alcohol, integrase strand inhibitor [INSTI] use, waist circumference, CD4 count). RESULTS: INSTI use nearly doubled from pre- to peri-HCV treatment. In unadjusted analysis, there was a 3.3% rate of rise in ELF pre-HCV treatment, 2.2% and 3.6% rate of decline during the peri- and 1-year post-HCV treatment period, respectively, followed by a 0.3% rise. Similar findings were observed for APRI and FIB-4. There was little effect on the estimated fibrosis trajectories after adjustment. CONCLUSIONS: The apparent lack of decline in biomarkers of liver fibrosis beyond 1 year after HCV cure suggests that continued monitoring of liver fibrosis and interventions to mitigate progression in people with HIV after HCV cure remains essential. date: 2023-06 date_type: published publisher: Oxford University Press (OUP) official_url: https://doi.org/10.1093/infdis/jiac315 oa_status: green full_text_type: other language: eng primo: open primo_central: open_green verified: verified_manual elements_id: 1970009 doi: 10.1093/infdis/jiac315 medium: Print-Electronic pii: 6650396 lyricists_name: Rosenberg, William lyricists_id: WMCRO67 actors_name: Rosenberg, William actors_id: WMCRO67 actors_role: owner funding_acknowledgements: U01-HL146241 [NIH HHS] full_text_status: public publication: Journal of Infectious Diseases volume: 227 number: 11 pagerange: 1274-1281 pages: 8 event_location: United States issn: 0022-1899 citation: Gardner, Annelys Roque; Ma, Yifei; Bacchetti, Peter; Price, Jennifer C; Kuniholm, Mark H; French, Audrey L; Gange, Stephen; ... Tien, Phyllis C; + view all <#> Gardner, Annelys Roque; Ma, Yifei; Bacchetti, Peter; Price, Jennifer C; Kuniholm, Mark H; French, Audrey L; Gange, Stephen; Adimora, Adaora A; Minkoff, Howard; Kassaye, Seble; Ofotokun, Igho; Rosenberg, William; Kovacs, Andrea AZ; Tien, Phyllis C; - view fewer <#> (2023) Longitudinal Assessment of the Enhanced Liver Fibrosis Score in the Era of Contemporary HIV and Hepatitis C Virus Treatment. Journal of Infectious Diseases , 227 (11) pp. 1274-1281. 10.1093/infdis/jiac315 <https://doi.org/10.1093/infdis%2Fjiac315>. Green open access document_url: https://discovery.ucl.ac.uk/id/eprint/10157002/1/ELF_trajectory_in_HIV-HCV_manuscript_revised%205-9-2022%20FINAL.pdf